Riskpilot← Back to searchSign inGet full accessPonsus Pharma AB
ABActiveOrg 5566622170VallentunaPatent brokering and marketing service activities · NACE 7491Est. 20040 employees
Revenue 2024
SEK 0
EBITDA margin
—
-12% vs 2023
Equity ratio
91.2%
Financial strength
Net profit 2024
SEK -9K
-12% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -9K | -12% |
| Net profit | SEK -9K | -12% |
| Total assets | SEK 114K | -78% |
| Equity | SEK 104K | -80% |
| Employees | 0 | — |
Legal name
Ponsus Pharma AB
Org number
5566622170
Legal form
Aktiebolag
NACE code
7491 · Patent brokering and marketing service activities
Founded
12 maj 2004
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall äga, förvalta, licensiera patent och andra rättigheter samt därmed förenlig verksamhet.
Address
Vallentuna
Phone
+46851188821
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | 0 | 0 | 8 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −6 | −6 | −6 | 29 | −6 | −6 | — | −30 | −8 | −9 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −6 | −6 | −6 | 29 | −6 | −6 | 0 | −30 | −8 | −9 |
| Net financials | — | 1 | — | — | — | — | — | — | — | — |
| Profit before tax | −6 | −5 | −6 | 29 | −6 | −6 | 0 | 12 | −8 | −9 |
| Tax | −0 | −0 | −0 | −1 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −6 | −5 | −6 | 28 | −6 | −6 | 0 | 12 | −8 | −9 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 389 | 964 | 538 | 532 | 526 | 519 | 519 | 531 | 523 | 114 |
| Equity | 504 | 499 | 493 | 521 | 515 | 509 | 509 | 521 | 513 | 104 |
| Long-term debt | 455 | 35 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 430 | 430 | 45 | 11 | 11 | 10 | 10 | 10 | 10 | 10 |
| Total debt | 885 | 465 | 45 | 11 | 11 | 10 | 10 | 10 | 10 | 10 |
EBITDA margin
-900000.0%
This company
15.8%
Market median
-5696303% vs market
20152024
Equity ratio
91.2%
This company
38.2%
Market median
+139% vs market
20152024
Return on equity
-8.7%
This company
18.4%
Market median
-147% vs market
20152024
Net profit margin
-900000.0%
This company
8.1%
Market median
-11111211% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
IM Audit | Audit | 2022 | — | — |
LB Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
EC Audit | Audit | 2022 | — | — |
MC Auditor Substitute | Auditor Substitute | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Aerosols Sweden AB | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Aerosols Sweden AB
Ponsus Pharma AB Board members of Ponsus Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ivan Mikael Larsson | Audit | 0 companies |
| Lars Blak | Chief Executive Officer | 0 companies |
| Eva Cajsa Marcelius | Audit | 0 companies |
| Malin Cecilia Markman | Auditor Substitute | 0 companies |
| Pär Erik Lindell | Board of Directors | 0 companies |
| Karin Maria Ulrika Kalderén | Deputy Board Member | 0 companies |